Closely held Aqua Medical is advancing therapy for gastrointestinal (GI) and metabolic diseases—including Type 2 diabetes—using its disruptive, transoral, outpatient vapor-based endoscopic ablation platform.
Cardiol Therapeutics (NASDAQ: CRDL; TSX: CRDL) is emerging as a leader in the development of anti-inflammatory and anti-fibrotic medicines designed to counteract the fundamental biological processes that drive...
Trevi Therapeutics (NASDAQ: TRVI) is advancing a fundamentally different approach to the treatment of chronic cough—a high unmet need that significantly affects the quality of life for millions of Americans.
Closely held Experity Health is shaping the future of healthcare by embedding AI into urgent care hubs across the U.S. to improve patient access, speed clinical visits, and elevate care quality.
Immuneering (NASDAQ: IMRX) is challenging conventional approaches of sustained inhibition in oncology by pioneering a novel class of therapies designed to outsmart cancer’s ability to adapt. With a proprietary platform...
Tyler B. Evans, MD, MS, MPH, is a leading voice in global health equity, infectious disease, and humanitarian medicine. As co-founder, CEO, and chief medical officer of Wellness Equity Alliance (WEA), Dr. Evans has...
Perimeter Medical Imaging AI (TSX-V:PINK; OTCQX:PYNKF) is an early stage commercial growth company that is pioneering a breakthrough, ultra-high-res, AI-driven intraoperative margin visualization technology called B...
Consultancy Cell One Partners is helping innovators translate scientific ambition into viable commercial solutions as the cell and gene therapy industry pushes toward its next era of breakthroughs. Through deep domain...
Exousia Pro (OTCPINK: MAJI) is developing a next-generation drug delivery platform using plant-based exosomes and a proprietary manufacturing process that could potentially address the biggest challenges in the...
Closely held Micoy Therapeutics is advancing novel, first-in-class therapeutics to target harmful autoantibodies that induce immunodeficiency by inhibiting immune signaling molecules—type I interferons—which are...